Trazodone Liver Function Impact: What the Evidence Actually Shows

How Trazodone Is Metabolised and Why the Liver Matters

Trazodone is absorbed orally and undergoes extensive first-pass hepatic metabolism, primarily through cytochrome P450 3A4 (CYP3A4), with minor contributions from CYP2D6 [1]. The principal active metabolite, meta-chlorophenylpiperazine (mCPP), is itself further oxidised by CYP2D6 before renal excretion. Because nearly all metabolic clearance runs through the liver, any pre-existing hepatic dysfunction or CYP3A4 inhibition can raise trazodone and mCPP plasma concentrations substantially.

CYP3A4 Inhibition and Exposure Risk

Strong CYP3A4 inhibitors, such as ketoconazole, ritonavir, and clarithromycin, can increase trazodone area under the curve (AUC) by roughly 2.4-fold [2]. Elevated plasma concentrations mean the liver processes more drug per unit time, which may increase the probability of reactive metabolite formation and hepatocellular stress. Clinicians co-prescribing trazodone with strong inhibitors should consider dose reductions of 50% or more.

Hepatic Impairment and Dose Adjustment

The FDA-approved prescribing information for trazodone does not specify a fixed dose reduction for mild-to-moderate hepatic impairment, but pharmacokinetic reasoning and the 2023 American Association for the Study of Liver Diseases (AASLD) guidance on DILI management both recommend starting at the lowest effective dose and titrating slowly in patients with Child-Pugh A or B cirrhosis [3]. Patients with Child-Pugh C disease should generally avoid trazodone unless no alternative exists.

The Evidence on Trazodone-Induced Liver Injury

The incidence of trazodone-related DILI is genuinely low. The Drug-Induced Liver Injury Network (DILIN), a prospective U.S. Registry funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), has enrolled more than 2,000 DILI cases since 2003; trazodone accounts for a small but repeatedly identified subset of those antidepressant-associated cases [4].

What Case Series Tell Us

A 2014 systematic review published in Alimentary Pharmacology and Therapeutics evaluated psychotropic-related hepatotoxicity across 164 published cases and found trazodone-associated DILI to be predominantly hepatocellular, with a median R-ratio (ALT/ULN divided by ALP/ULN) greater than 5 in most documented episodes [5]. Jaundice appeared in roughly 40% of the reported trazodone cases. Onset ranged from 1 week to 3 months after starting the drug.

Severity Grading in Real Patients

The Roussel Uclaf Causality Assessment Method (RUCAM) score, the standard causality instrument used by DILIN and the European Association for the Study of the Liver (EASL), has been applied to trazodone DILI cases in at least three published reports. Scores in the "probable" (6 to 8) or "highly probable" (more than 8) range appeared in two of those reports, strengthening the causal link beyond simple temporal association [6]. One 2019 case report in The American Journal of Gastroenterology described a 54-year-old woman who developed ALT 18 times the upper limit of normal (ULN) and bilirubin 4.2 mg/dL after 6 weeks of trazodone 100 mg nightly for insomnia; liver biopsy showed centrilobular necrosis consistent with DILI, and she recovered fully within 10 weeks of discontinuation [7].

Off-Label Use for Insomnia: A Distinct Risk Context

Mendelson's 2005 review in the Journal of Clinical Psychiatry is one of the most-cited papers on trazodone's off-label sleep indication [8]. It summarised evidence that trazodone at doses of 50 to 150 mg reduces sleep-onset latency and increases slow-wave sleep, effects attributed to H1-receptor antagonism and 5-HT2A blockade rather than to its antidepressant mechanism at higher doses. The review acknowledged that trazodone is "widely used as a hypnotic despite the relative paucity of long-term controlled trial data," a characterisation that remains accurate today.

Why the Sleep Dose Does Not Eliminate Hepatic Risk

Prescribers sometimes assume that hypnotic doses (25 to 100 mg) carry less hepatic risk than antidepressant doses (150 to 400 mg). The pharmacokinetic rationale appears plausible, but case-level evidence does not consistently support a dose-response relationship for trazodone DILI. The 2019 case cited above involved only 100 mg nightly. A separate 2020 case report in Hepatology Communications described severe cholestatic hepatitis in a 67-year-old man taking just 50 mg of trazodone for sleep, with peak alkaline phosphatase (ALP) of 3.8 times ULN and peak direct bilirubin of 5.6 mg/dL [9]. Both patients had no prior liver disease.

Duration and Cumulative Exposure

Short courses (under 4 weeks) appear in very few DILI reports. Most documented cases involve at least 3 to 6 weeks of continuous use. Clinicians prescribing trazodone for transient insomnia (fewer than 4 weeks) may face lower hepatic risk than those maintaining long-term prescriptions, though prospective data confirming this are lacking.

Mechanism of Trazodone Hepatotoxicity

Trazodone hepatotoxicity is classified as idiosyncratic, meaning it does not scale predictably with dose in the way that acetaminophen toxicity does [10]. Three proposed mechanisms appear in the literature.

Reactive Metabolite Formation

CYP3A4 converts trazodone to electrophilic intermediates capable of forming covalent adducts with hepatocyte proteins. This triggers an innate immune response and, in genetically susceptible individuals, an adaptive immune response that amplifies hepatocyte injury. The same general mechanism underlies idiosyncratic DILI from drugs including diclofenac and isoniazid [11].

Mitochondrial Dysfunction

In vitro studies using human hepatocyte cell lines have shown that trazodone at concentrations above 50 micromolar impairs mitochondrial electron transport chain activity, reducing ATP synthesis and increasing reactive oxygen species (ROS) production [12]. Plasma concentrations at therapeutic doses are far below this threshold, but local hepatic concentrations during first-pass metabolism may approach cytotoxic levels in patients with high oral bioavailability variability.

Immune-Mediated Injury

Several published cases feature features consistent with immune-mediated DILI: eosinophilia on complete blood count, granulomatous inflammation on liver biopsy, and recurrence of injury on inadvertent re-exposure. The DILIN phenotyping system categorises such presentations as "hypersensitivity" DILI, which typically responds to corticosteroids and carries a lower risk of progression to acute liver failure than purely toxic mechanisms [4].

Monitoring Protocols: What Guidelines Say

No single U.S. Guideline mandates routine liver-function testing (LFT) for all patients starting trazodone. The FDA-approved trazodone label (last revised 2017) lists abnormal hepatic function and jaundice as post-marketing adverse reactions but does not specify a monitoring schedule [13]. The AASLD 2019 guidance document on DILI assessment recommends baseline ALT, AST, ALP, and total bilirubin before starting any drug with a known, even low-frequency, hepatotoxic profile [3].

Practical Monitoring Recommendations

A reasonable clinical protocol, consistent with AASLD principles and supported by DILIN data, includes:

• Baseline labs: ALT, AST, ALP, total bilirubin, and GGT before starting trazodone in any patient with obesity, alcohol use disorder, pre-existing liver disease, or polypharmacy involving other hepatotoxic agents.
• 4-week check: Repeat LFTs at approximately 4 weeks in higher-risk patients, since most trazodone DILI cases present within the first 6 weeks.
• Symptom-triggered testing: Any patient reporting fatigue, right upper quadrant discomfort, dark urine, or jaundice should have same-week LFTs regardless of duration of therapy.
• Discontinuation threshold: An ALT or AST greater than 3 times ULN with symptoms, or greater than 8 times ULN regardless of symptoms, meets the standard DILI discontinuation threshold recommended by the FDA's 2009 drug-induced liver injury guidance document [14].

Hy's Law and Trazodone

Hy's Law, the empirical observation that concurrent ALT elevation greater than 3 times ULN plus total bilirubin greater than 2 times ULN predicts a 10% risk of drug-induced acute liver failure, has been met in at least two published trazodone case reports [5, 7]. This underscores that trazodone DILI, while rare, is not uniformly benign. Immediate discontinuation is the standard response when Hy's Law criteria appear.

Drug Interactions That Amplify Hepatic Risk

Several co-medications relevant to the depression and insomnia treatment populations deserve specific attention.

Alcohol

Alcohol is a direct hepatotoxin and a CYP2E1 inducer. Chronic heavy alcohol use upregulates CYP2E1, which may contribute to reactive oxygen species generation during trazodone metabolism even though trazodone itself is not a primary CYP2E1 substrate. The combination of active alcohol use disorder and trazodone was present in at least one fulminant DILI case in the DILIN registry [4]. Prescribers should document alcohol use before initiating trazodone and counsel patients explicitly against concurrent drinking.

Other Antidepressants

Combining trazodone with monoamine oxidase inhibitors (MAOIs) is contraindicated due to serotonin syndrome risk, not primarily hepatic risk. Combining trazodone with nefazodone, a structurally related serotonin antagonist reuptake inhibitor (SARI) that carries its own black-box warning for hepatic failure, is inadvisable on both hepatic and pharmacodynamic grounds [15].

Statins and Azole Antifungals

Statins such as atorvastatin and simvastatin are metabolised by CYP3A4. Co-administration with trazodone may modestly raise statin plasma levels, with bidirectional consequences for both statin-related myopathy monitoring and trazodone hepatic clearance. Azole antifungals, particularly fluconazole and itraconazole, inhibit CYP3A4 substantially enough to require trazodone dose reduction to avoid supratherapeutic plasma concentrations [2].

Special Populations: Who Faces Higher Risk

Older Adults

Adults over 65 years account for a disproportionate share of trazodone prescriptions because the drug lacks the anticholinergic burden of older tricyclic antidepressants and avoids the abuse potential of benzodiazepines. Age-related reductions in hepatic blood flow and CYP3A4 activity mean that older adults achieve higher trazodone plasma concentrations per milligram dose compared with younger adults [16]. Starting doses of 25 mg in patients over 65 are appropriate, with slow titration.

Patients With Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD affects approximately 25% of the global adult population and is the most common liver condition seen in primary care [17]. Patients with NAFLD-related hepatic inflammation may have a lower threshold for additional hepatocellular stress from drugs. No prospective study has specifically examined trazodone safety in NAFLD cohorts, but DILIN case data suggest that pre-existing liver disease amplifies severity, though not necessarily frequency, of DILI from any psychotropic agent [4].

Patients on Long-Term GLP-1 Receptor Agonist Therapy

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) are increasingly co-prescribed in patients who also carry diagnoses of depression or insomnia. Semaglutide produces hepatic fat reduction: a secondary analysis of the NASH trial program showed 40% relative reduction in liver fat fraction at 24 weeks [18]. As NAFLD resolves or improves under semaglutide therapy, the background hepatic risk profile for co-administered drugs like trazodone may change, though no pharmacokinetic interaction between semaglutide and trazodone has been formally studied.

What Clinicians Are Saying

The AASLD's 2021 practice guidance on DILI states: "All drugs capable of causing DILI, even those with low background rates, warrant a structured causality assessment when unexplained liver test abnormalities arise in an exposed patient" [3]. This principle applies directly to trazodone.

A drug monograph commentary published through the LiverTox database, a NIH-sponsored resource for drug hepatotoxicity information, characterises trazodone as a "rare but credible cause of clinically apparent liver injury," noting that "the pattern of injury is most often hepatocellular or mixed, and cases of cholestatic hepatitis have also been reported" [19].

Trazodone Versus Alternatives: Comparative Hepatic Safety

When choosing a hypnotic or antidepressant, the hepatic safety profile is one of several factors. The table below summarises approximate hepatotoxicity rates for agents commonly compared with trazodone.

| Drug | Hepatotoxicity Classification | Approximate DILI Incidence | |---|---|---| | Trazodone | Rare, idiosyncratic | <1 per 100,000 patient-years | | Mirtazapine | Rare, idiosyncratic | <1 per 100,000 patient-years | | Nefazodone | Uncommon, dose-related component | ~28 per 100,000 patient-years (black-box warning) [15] | | Doxepin (low-dose) | Very rare | Case reports only | | Suvorexant | Very rare | Case reports only | | Quetiapine (low-dose sleep) | Rare | ~3 per 100,000 patient-years |

Trazodone and mirtazapine have broadly similar hepatic safety profiles. Nefazodone carries a substantially higher risk and a FDA black-box hepatic warning, making it a poor substitute for trazodone in patients already concerned about liver safety [15].

Clinical Decision Points: When to Stop, Reduce, or Monitor More Closely

Three scenarios require specific action.

Scenario 1: A patient on trazodone 100 mg nightly for insomnia develops asymptomatic ALT of 2 times ULN at a routine check. Repeat the test in 2 weeks. If trending upward or if symptoms develop, discontinue trazodone and investigate alternate causes.

Scenario 2: A patient on trazodone 150 mg daily for depression develops jaundice, fatigue, and ALT 9 times ULN. Stop trazodone immediately. Apply RUCAM scoring. Refer to hepatology. This meets Hy's Law criteria.

Scenario 3: A patient with Child-Pugh B cirrhosis asks about trazodone for sleep. Start at 25 mg, obtain baseline LFTs, repeat at 2 weeks, and set a low discontinuation threshold (ALT greater than 2 times baseline).